NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
List view / Grid view
Merck Sharp & Dohme
Filter the results
NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.
20 July 2015 | By Victoria White
Results of the first Phase 2a study of lonafarnib in patients with chronic hepatitis delta virus (HDV) infection have been published...
Syndax and Merck to collaborate on immuno-oncology study evaluating entinostat in combination with Keytruda in lung cancer and melanoma
31 March 2015 | By Victoria White
Syndax and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining entinostat with Keytruda (pembrolizumab)...
Inspection of incoming raw materials is an essential step in the pharmaceutical industry to verify that the correct raw material which meets the quality specifications has been received. It will not only help to ensure that the final product is of best quality and minimise wasted time, material costs and…
20 June 2011 | By Willem G.E.J. Schoonen, Walter M.A. Westerink, Femke M. van de Water and G. Jean Horbach, Department of Toxicology & Drug Disposition, Merck Sharp & Dohme
The application of High Content Screening for in vitro toxicity testing is a relatively new approach in the preclinical research phase of drug development. A battery of tests have been developed for screening on general parameters such as cytotoxicity, while more dedicated assays are available with respect to the identification…
9 November 2010 | By NG Online News
Senior executives from Eli Lilly, AstraZeneca, Johnson and Johnson & Pfizer to discuss the ROI for "non-surrogate" biomarkers, dose selection biomarkers and biomarkers of efficacy.